How does pharmacogenomics (PGx) fit or fail to fit within the current systems of financing and organization of health care? The researcher (1) gathered information and summarize the PGx products and services available now or in the near term; (2) conducted open-ended interviews of key informants regarding the way suppliers are bringing these products to market; and (3) studied the implications for financing and the organization of the delivery system, including reimbursement rules, for at least three current health care products and services that are being affected or replaced by PGx in the near future. The objective of this study was to suggest ways in which current payment methods could be changed to accommodate PGx and how a larger study could use patient-level claims data to design changes or a new system to recognize PGx.